Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2023

Genmab — Juli 2023

Planlagt Fastgjort Låst Flyttet Genmab
551 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #94

    Er lige nu i DH 🙂

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #95

      fedt;-)

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #96

        Link Preview Image
        Genmab Breaks Above 200-Day Moving Average - Bullish for GMAB

        In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $39.58, changing hands as high as $39.70 per share. Genmab A/S shares are currently trading up about 2.2% on the day. The chart below shows the one year performance of GMAB

        favicon

        (www.nasdaq.com)

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #97

          Dejligt når man npede at kæbe Bulld i onsdag. Skal bare ligge og modne hen over so

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #98

            Prøver lige igen - dejligt med stigningerne når man nåede at købe Bulls i onsdag.

            1 Reply Last reply
            0
            • P Offline
              P Offline
              Pensionisten
              wrote on sidst redigeret af
              #99

              lahn1. synes nu, at dit indlæg 21:55 var bedst 😄

              1 Reply Last reply
              0
              • J Offline
                J Offline
                JKY_VH
                wrote on sidst redigeret af
                #100

                😄

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  Pensionisten
                  wrote on sidst redigeret af
                  #101

                  Lidt lidt ærgerligt, at børsen først åbner mandag morgen 🙂

                  1 Reply Last reply
                  0
                  • nohopeN Offline
                    nohopeN Offline
                    nohope
                    wrote on sidst redigeret af
                    #102

                    Det synes jeg også. https://imgur.com/a/WXOd1T8

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      lahn1
                      wrote on sidst redigeret af
                      #103

                      God morgen, det blev lidt sent igår 😄

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #104

                        Nohope hvad er det som giver 100+% på en dag ?

                        1 Reply Last reply
                        0
                        • nohopeN Offline
                          nohopeN Offline
                          nohope
                          wrote on sidst redigeret af
                          #105

                          Når der er fejl på Nordnet.

                          1 Reply Last reply
                          0
                          • nohopeN Offline
                            nohopeN Offline
                            nohope
                            wrote on sidst redigeret af
                            #106

                            Ellers lækker fejl.

                            1 Reply Last reply
                            0
                            • nohopeN Offline
                              nohopeN Offline
                              nohope
                              wrote on sidst redigeret af
                              #107

                              De har desværre rettet den her til morgen.

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #108

                                Købte engang Bull som ikke var korrigeret ved udbytte betaling på dagen (det galt alle certifikater fra samme udbyder) . Klar fejl og tjekkede i en periode ved udbyttebetalinger på div aktier om de lavede samme fej, men desværre.

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #109

                                  Johnson & Johnson Poised For A Muted Q2? https://www.proinvestor.com/investornyt/1015967/johnson-amp-johnson-poised-for-a-muted-q2

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #110

                                    Antengene : Xpovio Approved In Hong Kong For Relapsed And/or Refractory Multiple Myeloma Treatment https://www.proinvestor.com/investornyt/1015963/antengene-xpovio-approved-in-hong-kong-for-relapsed-and-or-refractory-multiple-myeloma-treatment

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #111

                                      Caribou Biosciences has reported new follow-up data from the dose-escalation portion of its ongoing Phase I ANTLER study, which is evaluating the allogeneic anti-CD19 CAR-T therapy CB-010 in 16 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) https://firstwordpharma.com/story/5761039?aid=5761039

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #112

                                        Both epcoritamab and talquetamab on the CHMP agenda this week https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-17-20-july-2023_en.pdf

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #113

                                          Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival https://www.researchgate.net/publication/372343645_Daratumumab_in_first-line_treatment_of_patients_with_light_chain_amyloidosis_and_Mayo_stage_IIIb_improves_treatment_response_and_overall_survival

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper